melanoma

Melanoma, anyone?

Collegiate tennis and golf athletes aren’t using enough sunscreen according to a recent survey; meanwhile, the deadly skin cancer melanoma is on the rise.

Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.

Research by Ann Richmond, PhD, second from left, Chi Yan, PhD, left, Kensey Bergdorf, PhD, JinMing Yang, PhD, and colleagues is leading to new insights on melanoma tumor formation and growth.

Study identifies key regulator of melanoma development

Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.

Luke and Susan Simons recently made a gift to establish the Susan and Luke Simons Directorship at Vanderbilt-Ingram Cancer Center.

Couple’s gift helps support immunotherapy research

Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.

Melanoma treatment response

Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.

Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.

1 2 3